Retained Earnings (Accumulated Deficit) of China SXT Pharmaceuticals, Inc. from 31 Mar 2018 to 31 Mar 2025

Taxonomy & unit
us-gaap: USD
Description
The cumulative amount of the reporting entity's undistributed earnings or deficit.
Summary
China SXT Pharmaceuticals, Inc. quarterly Retained Earnings (Accumulated Deficit) in USD history and change rate from 31 Mar 2018 to 31 Mar 2025.
  • China SXT Pharmaceuticals, Inc. Retained Earnings (Accumulated Deficit) for the quarter ending 31 Mar 2025 was $28,015,317, a 13% decline year-over-year.
Source SEC data
View on sec.gov
Retained Earnings (Accumulated Deficit), Quarterly (USD)
Retained Earnings (Accumulated Deficit), YoY Quarterly Change (%)

China SXT Pharmaceuticals, Inc. Quarterly Retained Earnings (Accumulated Deficit) (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $28,015,317 -$3,303,652 -13% 31 Mar 2025 20-F 31 Jul 2025 2025 FY
Q3 2024 $25,514,233 +$5,795,058 +19% 30 Sep 2024 6-K 28 Mar 2025 2025 Q2
Q1 2024 $24,711,665 -$3,098,532 -14% 31 Mar 2024 20-F 31 Jul 2025 2025 FY
Q3 2023 $31,309,291 -$14,126,404 -82% 30 Sep 2023 6-K 05 Apr 2024 2024 Q2
Q1 2023 $21,613,133 -$5,924,855 -38% 31 Mar 2023 20-F 13 Aug 2024 2024 FY
Q3 2022 $17,182,887 -$4,138,880 -32% 30 Sep 2022 6-K 24 Feb 2023 2023 Q2
Q1 2022 $15,688,278 -$5,736,095 -58% 31 Mar 2022 20-F 31 Jul 2023 2023 FY
Q3 2021 $13,044,007 -$7,221,265 -124% 30 Sep 2021 6-K 14 Jan 2022 2022 Q2
Q1 2021 $9,952,183 -$2,748,183 -38% 31 Mar 2021 20-F/A 19 May 2023 2022 FY
Q3 2020 $5,822,742 -$6,558,545 -891% 30 Sep 2020 6-K 28 Jan 2021 2021 Q2
Q1 2020 $7,204,000 -$10,287,872 -334% 31 Mar 2020 20-F 13 Aug 2021 2021 FY
Q3 2019 $735,803 30 Sep 2019 6-K/A 22 May 2020 2020 Q2
Q1 2019 $3,083,872 +$1,539,227 +100% 31 Mar 2019 20-F 31 Jul 2020 2020 FY
Q1 2018 $1,544,645 31 Mar 2018 20-F 15 Aug 2019 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.